Presentation Outline ICHP Annual Meeting September 13-15

3 Months of Treatment for Latent TB
• Statistics
– Expected event rate of 1.5% in INH group
– Noninferiority margin set at 0.75% (upper limit)
– 3200 subjects/group provide power of 80% to
show noninferiority of combination group to
isoniazid‐only group
N Engl J Med. 2011;365(23):2155-2166.
3 Months of Treatment for Latent TB
• Demographics
– Median age 35
– 54% male
– 57% white, 25% black
– 89% from U.S. or Canada
– 57% completed HS
– 2% were HIV‐infection and very few had HBV, HCV
– 50% had a history of EtOH use
– >25% were current smokers
N Engl J Med. 2011;365(23):2155-2166.
3 Months of Treatment for Latent TB
• Overall, patients considered high‐risk
• 322 ineligible: drug‐resistant or Cx‐negative
source cases
• Mean number b of f months h iin study d ~30 30
• Completion of 33 months
– Combination group: 88%
– Isoniazid group: 86%
N Engl J Med. 2011;365(23):2155-2166.
8/30/2012
22